Teclistamab in multiple myeloma with one to three previous lines of therapy

This study compared teclistamab to standard therapies (PVd or Kd) in patients with relapsed or refractory multiple myeloma after 1 to 3 previous lines of treatment. Teclistamab significantly improved progression-free and overall survival, achieving a 65.9% complete response rate. However, grade 3 or 4 infections and cytokine release syndrome were notably more frequent with teclistamab.